Next Article in Journal
Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from Californiconus californicus, for Treating Type 2 Diabetes
Next Article in Special Issue
Immunity and Breast Cancer: Focus on Eosinophils
Previous Article in Journal
Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo
Review

Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?

1
Third Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
2
Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editor: Concetta Elisa Onesti
Biomedicines 2021, 9(8), 935; https://doi.org/10.3390/biomedicines9080935
Received: 30 June 2021 / Revised: 19 July 2021 / Accepted: 27 July 2021 / Published: 1 August 2021
(This article belongs to the Special Issue New Advance in Immuno-Oncology)
Soft tissue sarcomas (STSs) are rare mesenchymal tumors. With more than 80 histological subtypes of STSs, data regarding novel biomarkers of strong prognostic and therapeutic value are very limited. To date, the most important prognostic factor is the tumor grade, and approximately 50% of patients that are diagnosed with high-grade STSs die of metastatic disease within five years. Systemic chemotherapy represents the mainstay of metastatic STSs treatment for decades but induces response in only 15–35% of the patients, irrespective of the histological subtype. In the era of immunotherapy, deciphering the immune cell signatures within the STSs tumors may discriminate immunotherapy responders from non-responders and different immunotherapeutic approaches could be combined based on the predominant cell subpopulations infiltrating the STS tumors. Furthermore, understanding the immune diversity of the STS tumor microenvironment (TME) in different histological subtypes may provide a rationale for stratifying patients according to the TME immune parameters. In this review, we introduce the most important immune cell types infiltrating the STSs tumors and discuss different immunotherapies, as well as promising clinical trials, that would target these immune cells to enhance the antitumor immune responses and improve the prognosis of metastatic STSs patients. View Full-Text
Keywords: sarcoma; immunotherapy; checkpoint inhibitors; adoptive transfer; trabectedin; IL-15; tumor microenvironment; TILs; immune cells sarcoma; immunotherapy; checkpoint inhibitors; adoptive transfer; trabectedin; IL-15; tumor microenvironment; TILs; immune cells
Show Figures

Figure 1

MDPI and ACS Style

Ozaniak, A.; Vachtenheim, J., Jr.; Lischke, R.; Bartunkova, J.; Strizova, Z. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective? Biomedicines 2021, 9, 935. https://doi.org/10.3390/biomedicines9080935

AMA Style

Ozaniak A, Vachtenheim J Jr., Lischke R, Bartunkova J, Strizova Z. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective? Biomedicines. 2021; 9(8):935. https://doi.org/10.3390/biomedicines9080935

Chicago/Turabian Style

Ozaniak, Andrej, Jiri Vachtenheim Jr., Robert Lischke, Jirina Bartunkova, and Zuzana Strizova. 2021. "Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?" Biomedicines 9, no. 8: 935. https://doi.org/10.3390/biomedicines9080935

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop